anti- PARP1 antibody FNab06151
Background:
This gene encodes a chromatin-associated enzyme, poly(ADP-ribosyl)transferase, which modifies various nuclear proteins by poly(ADP-ribosyl)ation. The modification is dependent on DNA and is involved in the regulation of various important cellular processes such as differentiation, proliferation, and tumor transformation and also in the regulation of the molecular events involved in the recovery of cell from DNA damage. In addition, this enzyme may be the site of mutation in Fanconi anemia, and may participate in the pathophysiology of type I diabetes.
Clonality:
polyclonal
Classification:
Primary antibody
Alternative names:
ADPRT, PPOL
Specificity:
Human, Rat
Host:
Rabbit
Isotype:
IgG
Immunogen:
poly (ADP-ribose) polymerase 1
Purification:
Immunogen affinity purified
Purity:
≥95% as determined by SDS-PAGE
Calculated molecular weight:
115 kDa
Form:
liquid
Applications:
ELISA, WB, IHC
Recommended dilution:
WB: 1:500 - 1:2000; IHC: 1:50 - 1:100
Storage:
PBS with 0.02% sodium azide and 50% glycerol pH 7.3 , -20℃ for 12 months (Avoid repeated freeze / thaw cycles.)
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com
Fine Biotech is an ISO9001:2008 Certified Company,offers a full line of quality research kits,which include ELISA Kits,related ELISA assistant reagents and more high quality antibodies, recombinant proteins. Fine Biotech technical support are delicated to providing with professional and friendly assistance for our customers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality,rapid turnaround and personal support for all FineTest services are guaranteed. Should you have any problems,or any ideas on ways that we can improve our service,please feel free to call upon us.Thank you for your interest in FineTest products and we look forward to supplying you in the near future.